Maresin1 is a predictive marker of new digital ulcers in systemic sclerosis patients.

Abstract

Digital ulcers (DUs) are one of the main causes of disability among systemic sclerosis (SSc) patients. The inflammation plays a crucial role in mediating the pathophysiological process underlying SSc. Objective of this study was to evaluate Maresin1 (MaR1) serum levels in SSc patients and in healthy controls (HC). Secondary aims were to evaluate the relationship between MaR and diseases variables and to assess the predictive role of MaR1 in the development of new digital ulcers (DUs) during 18weeks follow-up. MaR1 serum level was evaluated in 55 SSc patients and 24 HC. In SSc patients, clinical assessment was performed at baseline and after 18week follow-up by the same-blinded observer on serum MaR1 levels. MaR1 was significantly lower in SSc patients than in HC [367pg/ml (IQR 304-468.3pg/ml) vs 467.7pg/ml (IQR 422-522pg/ml), p<0.001]. During follow-up, six patients (10.9%) developed DUs. MaR1 was higher in SSc patients with new DUs than in patients without new DUs [518.2pg/ml (IQR 468.2-596.5pg/ml) vs 355pg/ml (IQR 299.8-444.7pg/ml), p<0.01]. Free survival from new DUs is significantly lower in SSc patients with increased MaR1 serum level than in SSc patient with normal MaR1 serum level. In multivariate analysis, serum level of MaR1>393.2pg/ml is a predictive marker for new DUs. In SSc patients, MaR1 is reduced compared to HC and it is a predictive marker of new DUs.